Healthcare Realty Shorts Retreat as Print Looms
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
HR heads into today's Q2 earnings with short sellers backing away and options traders turning notably more cautious, creating a split signal into the release.
The clearest shift in positioning is on the short side — and it points to retreat, not aggression. Short interest has fallen nearly 7.5% over the past week to roughly 4.9% of the free float, continuing a drawdown from a mid-July peak near 5.7% of float. That move lower is reinforced by a deeply relaxed borrow market: availability runs at around 916% — meaning for every share currently borrowed, more than nine sit unused in the lending pool. Cost to borrow has also eased, dropping more than 20% over the month to just 0.39%. For a stock up 4% over the past month and 28% year-to-date, the shorts are not pressing their case.
Options tell a different story. Defensive positioning has jumped to its most elevated level in several weeks. The put/call ratio hit 0.16 on Wednesday — nearly 2.4 standard deviations above its 20-day average of 0.09. That's a sharp and sudden spike from a prolonged flat stretch in the 0.087–0.088 range that lasted most of July, suggesting traders bought downside protection specifically in the two sessions immediately before the print. HR fell 1.3% on Wednesday, its first meaningful one-day decline in recent weeks, to close at $21.53.
The analyst community has converged on a cautious consensus. The headline rating is a hold, with nine holds recorded and no buys from the most recent update. JP Morgan and UBS both lifted their price targets to $21 in early July — essentially matching the current price, implying the Street sees no near-term upside from here. Raymond James is the outlier: it reinstated coverage in mid-June with an Outperform and a $24 target, arguing the REIT's 36 million square feet of medical office portfolio and higher-than-expected rent growth justify a premium. Bears counter that NAV has been declining, occupancy remains under pressure, and the 28% year-to-date rally has already compressed any valuation buffer. The EV/EBITDA multiple has drifted lower over the past month, and EPS momentum ranks near the bottom of the universe at the 2nd percentile on a 30-day basis — a sign that estimate cuts have been running ahead of the price.
Institutional ownership offers one supporting note: BlackRock added over 1.2 million shares in the most recent quarter to hold nearly 16% of the company, and T. Rowe Price added another million shares. With the stock's one prior earnings reaction on record showing a 4.7% one-day gain and 7.8% five-day gain following the May print, today's release tests whether HR can demonstrate the occupancy recovery and rent growth needed to justify a valuation that has now outrun the majority of analyst targets.
Stocks in this article
See the live data behind this article on ORTEX.
Open HR on ORTEX →How this article was generated
- Generated
- 31 Jul 2026, 04:27
- Data as of
- 31 Jul 2026, 04:01
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsInstitutional positioningORTEX Alpha signalsRecent ORTEX notes
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.